�@—Õ�°–òŠw

 

’˜�@�‘

 

1)�@�¼Œû�HŽi�Fˆã—ÖòŠw�m‘æ6”Å�n�C–x—¹•½�AŠ£Œ«ˆê�A‰œ‘º�Ÿ•FŠÄ�C�CœA�ì�‘“X�o”Å (2014).

 

2)�@�¼Œû�HŽi�FƒVƒiƒŠƒI�@�Ç—á‰ð�Í�\ˆã—Â̌»�ê‚Å�¡�\[‘æ2”Å]�CûüŽR–¾‘�•Ò�W�C‹ž“sœA�ì�‘“X�o”Å

    (2014).

 

˜_�@•¶

 

1)       “’ŒŽãÄ‘¾�A•õŠ_“N–ç�A”Œˆä—�ŒbŽq�A“¡ˆä�®Žq�Aà_“c”ü‹P�AŽá—Ñ–¢‹H�A�Ⓦ‹G•zŽq�A‹{�¼—ljÀ�A–àˆä‰À“Þ�A’Ò–{‰ë”V�A�¼Œû�HŽi. ƒAƒ€ƒ�ƒWƒsƒ“ƒxƒVƒ‹Ž_‰–�»�܂Ǝ_‰»ƒ}ƒOƒlƒVƒEƒ€�»�܂̓¯ŽžŠÈˆÕŒœ‘÷‚É‚æ‚éŽå–ò—ʂ̕ϓ®. ˆã—ÖòŠw40, 252-257 (2014).

 

2)       Hitoshi Uchiyama, Masayuki Tsujimoto, Tadakazu Shinmoto, Hitomi Ogino, Tomoko Oda, Takuya Yoshida, Taku Furukubo, Satoshi Izumi, Tomoyuki Yamakawa, Hidehisa Tachiki, Tetsuya Minegaki and Kohshi Nishiguchi. Uremic Toxins enhance statin-Induced cytotoxicity in differentiated human rhabdomyosarcoma cells.  Toxins, 6, 2612-2625 (2014).

 

3)       Masayuki Tsujimoto, Sari Sugimoto, Makiko Nagatomo, Taku Furukubo, Satoshi Izumi, Tomoyuki Yamakawa, Tetsuya Minegaki, and Kohshi Nishiguchi. Possibility of decrease in CYP1A2 function in patients with end-stage renal disease.  Therapeutic Apheresis and Dialysis, 18, 174-180 (2014).

 

4)       Kyoko Seki, Yasuo Tsuduki, Takeshi Ioroi, Michiko Yamane, Hiroko Yamauchi, Yukinari Shiraishi, Tadaaki Ogawa, Izumi Nakata, Kohshi Nishiguchi, Teruhisa Matsubayashi, Yoshihide Takakubo, Motohiro Yamamori, Akiko Kuwahara, Noboru Okamura, and Toshiyuki Sakaeda. Serum lactate dehydrogenase  levels as a predictive marker of oxaliplatin-induced hypersensitivity reactions in Japanese patients with advanced colorectal cancer.  Int.J.Med.Sci.11, 641-645 (2014).

 

5)       Tetsuya Minegaki, Akiko Kuwahara, Motohiro Yamamori, Tsutomu Nakamura, Tatsuya Okuno, Ikuya Miki, Hideaki Omatsu, Takao Tamura, Midori Hirai, Takeshi Azuma, Toshiyuki Sakaeda, and Kohshi Nishiguchi. Genetic polymorphisms in SLC23A2 as predictive biomarkers of severe acute toxicities after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma .  Int.J.Med.Sci.11, 321-326(2014).

 

 

 

‰ð�à�A•ñ���‘“™

 

1)      �¼Œû�HŽi�FDo you know?�|POCT�|“ú–{•a‰@–ò�ÜŽt‰ïŽGŽ�, 50, 141 (2014).

 

2)�@�¼Œû�HŽi�FDo you know? �|Syk‘jŠQ–ò�|“ú–{•a‰@–ò�ÜŽt‰ïŽGŽ�, 50 , 900 (2014).

 

Šw‰ï”­•\“™

 

�@Šw‰ï”­•\

 

1)      �¼–{ŒõŽi�A’Ò–{‰ë”V�A‹g“c‘ñ–í�A�Z–{�Ø“E�A�{–{�^—�Žq�A’†�ì’q‰Á�A�¬�ì‰À�D�A�_Œ´Œ’Œá�A’¹‹�“Þ‰›�A“ü�]—TŽq�A�ì�ã�Ë‘ã�A’†’J�¹‹I�A“¡‰ª�t”T�A•õŠ_“N–ç�A�¼Œû�HŽi�FƒAƒŠƒXƒLƒŒƒ“‚ÌŠÌ�Áޏ‰ß’ö‚É‹y‚Ú‚·—L‹@ƒAƒjƒIƒ“—A‘—ƒ|ƒŠƒyƒvƒ`ƒh1‚a1‚̉e‹¿�D“ú–{–òŠw‰ï‘æ134”N‰ï (ŒF–{), 2014.3.

 

2)      “›ˆä�FŽ¡�A’Ò–{‰ë”V�A“àŽR�m�A“‡“c“Þ‰›”ü�A�V“c�ʉÀ�A–Ø‘ºŽé—›�A�²”Œ�’�AŒ‹�éŠG—�Žq�A‹g“c‘ñ–í�AŒÃ‹v•Û‘ñ�A˜a�ò’q�AŽR�ì’q”V�A•õŠ_“N–ç�A—§–Ø�G�®�A�¼Œû�HŽi�F––Šú�t•s‘SгŽÒŒŒ�´‚ð’·Šú–\˜I‚µ‚½‰¡–䋨�×–E‚Ì�ì�»‚Æ‚»‚Ì‹@”\•]‰¿�D“ú–{–òŠw‰ï‘æ134”N‰ï (ŒF–{), 2014.3.

 

3)      “àŽR�m�A’Ò–{‰ë”V�A‰¬–ì�m–¢�A�¬“c’qŽq�A�V–{—Bˆê�A“‡“c“Þ‰›”ü�A“›ˆä�FŽ¡�A�V“c�ʉÀ�A‹g“c‘ñ–í�AŒÃ‹v•Û‘ñ�A˜a�ò’q�AŽR�ì’q”V�A•õŠ_“N–ç�A—§–Ø�G�®�A�¼Œû�HŽi�Fƒqƒg‰¡–䋨ƒ‚ƒfƒ‹�×–E‚ð—p‚¢‚½ƒXƒ^ƒ`ƒ“‚É‚æ‚鉡–䋨�áŠQ‚Ö‚Ì”A“Å�Ç•¨Ž¿‚ÌŠÖ—^‚Æ‚»‚Ì‘�‹­ƒ�ƒJƒjƒYƒ€‚ÌŒŸ“¢�D“ú–{–òŠw‰ï‘æ134”N‰ï (ŒF–{), 2014.3.

 

4)      •Ÿ“‡�¹�D�A•õŠ_“N–ç�A‰F–ì�‡‹R�A�‚—œ�m”ü�A�X‰ª�ç�q�A’Òžx�AŽR–{’mŽu�A“n糈¤—œ�A’Ò–{‰ë”V�A�¼Œû�HŽi�Fƒqƒg�H“¹Šà�×–EŠ”‚Ì‘��B‚É‹y‚Ú‚·ƒrƒXƒzƒXƒzƒl�[ƒgŒn–ò•¨‚̉e‹¿�D“ú–{–òŠw‰ï‘æ134”N‰ï (ŒF–{), 2014.3.

 

5)      ‹g“c‘ñ–í�A’Ò–{‰ë”V�A�Z–{�Ø“E�A�{–{�^—�Žq�A’†�ì’q‰Á�A�¼–{ŒõŽi�A“ü�]—TŽq�A�ì�ã�Ë‘ã�A’†’J�¹‹I�A“¡‰ª�t”T�A•õŠ_“N–ç�A�¼Œû�HŽi�F�Á‰»ŠÇƒ‚ƒfƒ‹Caco-2�×–E‚É‚¨‚¯‚é”AŽ_‚ƃCƒ“ƒhƒLƒVƒ‹—°Ž_‚Ì‘ŠŒÝ�ì—p‚ÉŠÖ‚·‚é“®‘ÔŠw“IŒ¤‹†�Dˆã—ÖòŠwƒtƒH�[ƒ‰ƒ€2014�^‘æ22‰ñƒNƒŠƒjƒJƒ‹ƒtƒ@�[ƒ}ƒV�[ƒVƒ“ƒ|ƒWƒEƒ€ (“Œ‹ž), 2014.6.

 

6)      Žá—Ñ–¢‹H�A•õŠ_“N–ç�Aà_“c”ü‹P�A�M‘¾Œb—��Ø�A’†“‡���D�A•s”j“O�A�óˆä–ƒ—C—¢�A‘å�¼Œ‹Šó�A“¡–{”ü�¹‹I�A’Ò–{‰ë”V�A�¼Œû�HŽi�FŠÈˆÕŒœ‘÷–@‚É‚¨‚¯‚éƒWƒqƒhƒ�ƒsƒŠƒWƒ“ŒnCa�h�R–ò‚ÆŽ_‰»ƒ}ƒOƒlƒVƒEƒ€�ù‚Ì”z�‡•ω»�Dˆã—ÖòŠwƒtƒH�[ƒ‰ƒ€2014�^‘æ22‰ñƒNƒŠƒjƒJƒ‹ƒtƒ@�[ƒ}ƒV�[ƒVƒ“ƒ|ƒWƒEƒ€ (“Œ‹ž), 2014.6.

7)      Masayuki Tsujimoto, Hitoshi Uchiyama, Tadakazu Shinmoto, Hitomi Ogino, Tomoko Oda, Takuya Yoshida, Taku Furukubo, Satoshi Izumi, Tomoyuki Yamakawa, Hedehisa Tachiki, Tetsuya Minegaki, Kohshi Nishiguchi: Effect of uremic toxins on statin-induced cytotoxicity in patients with end-stage renal failure. 2014 Annual Meeting American College of Clinical Pharmacology (Atlanta, GA, USA), 2014.9.

 

8)      –kŽR—z�Ø�A’Ò–{‰ë”V�AŽ›”ö�Ê�A•Ÿ“c’q�Æ�A�ì’[”ü•ä�AœA�숤�AŽR“c—L—¢Žq�A•õŠ_“N–ç�A�¼Œû�HŽi�F�¶‘Ì“à•K�{”÷—ÊŒ³‘f—ʂ̕ϓ®‚ªCYP3A4‹@”\‚É‹y‚Ú‚·‰e‹¿�D‘æ24‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ï (–¼ŒÃ‰®), 2014.9.

 

9)      •õŠ_“N–ç�A�X‰ª�ç�q�A•Ÿ“‡�¹�D�A�‚—œ�m”ü�A‰F–ì�‡‹R�A’Òžx�AŽR–{’mŽu�A“n糈¤—œ�A’Ò–{‰ë”V�A�¼Œû�HŽi�FƒrƒXƒzƒXƒzƒl�[ƒgŒn–ò•¨‚̃qƒg�H“¹Šà�×–EŠ”‚ɑ΂·‚é�×–E“Å�«ƒ�ƒJƒjƒYƒ€‚̉ð–¾�D‘æ24‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ï (–¼ŒÃ‰®), 2014.9.

 

10)   �¬�o”Ž‹`�A’Ò–{‰ë”V�A�Z–{�Ø“E�A�{–{�^—�Žq�A’†�ì’q‰Á�A�¼–{ŒõŽi�A�¬�ì‰À�D�A�_Œ´Œ’Œá�A’¹‹�“Þ‰›�A“ü�]—TŽq�A�ì�ã�Ë‘ã�A’†’J�¹‹I�A“¡‰ª�t”T�A‹g“c‘ñ–í�A•õŠ_“N–ç�A�¼Œû�HŽi�FƒVƒNƒ�ƒXƒ|ƒŠƒ“‚É‚æ‚éƒAƒŠƒXƒLƒŒƒ“�Áޏ’x‰„‚Ö‚Ì—L‹@ƒAƒjƒIƒ“—A‘—ƒ|ƒŠƒyƒvƒ`ƒh1B1‚ÌŠÖ—^‚ÉŠÖ‚·‚錟“¢�D‘æ64‰ñ“ú–{–òŠw‰ï‹ß‹EŽx•”‘�‰ï�E‘å‰ï (‹ž“s), 2014.10.

 

11)   �Ÿ•”—F—�Œb�A’Ò–{‰ë”V�A—Ž�‡ˆ¤�A�¬�o”Ž‹`�A–k�ðˆŸ–îŽq�A�Z–{�Ø“E�A�{–{�^—�Žq�A’†�ì’q‰Á�A�¼–{ŒõŽi�A�¬�ì‰À�D�A�_Œ´Œ’Œá�A’¹‹�“Þ‰›�AŽu–€‘å‰î�AŒÃ‹v•Û‘ñ�A˜a�ò’q�AŽR�ì’q”V�A•õŠ_“N–ç�A�¼Œû�HŽi�FƒCƒŠƒmƒeƒJƒ“Šˆ�«‘ãŽÓ•¨SN-38ŠÌŽæ‚è�ž‚݂ɋy‚Ú‚·”A“Å�Ç•¨Ž¿‹y‚уAƒ‹ƒuƒ~ƒ“‚̉e‹¿�D‘æ64‰ñ“ú–{–òŠw‰ï‹ß‹EŽx•”‘�‰ï�E‘å‰ï (‹ž“s), 2014.10.

 

12)   “n糈¤—œ�A•õŠ_“N–ç�A’Òžx�AŽR–{’mŽu�Aœö–Ø�¹–ë�A“¹‰Æ—Y‘¾˜Y�AŽR�ª�ç�q�A’Ò–{‰ë”V�A�¼Œû�HŽi�F5-FU‘Ï�«ƒqƒg“ûŠà�×–EŠ”‚ÌŽ÷—§‚Æ‚»‚̃�ƒJƒjƒYƒ€‚̉ð–¾�D‘æ64‰ñ“ú–{–òŠw‰ï‹ß‹EŽx•”‘�‰ï�E‘å‰ï (‹ž“s), 2014.10. —D�Gƒ|ƒXƒ^�[�ÜŽó�Ü

 

13)   ’I‹´�^ŽÀ�A•õŠ_“N–ç�A‹{–{Œb•ã�AŽR–{�ʉÀ�A�r–Ø—I�AˆîŠ_Œb–¢�A—ÑŠG—¢�A’Ò–{‰ë”V�A�¼Œû�HŽi�F�H“¹Šà�×–EŠ”‚É‚¨‚¯‚éPARP‘jŠQ�Ü‚Æ�×–E�áŠQ�«�RŠà�܂Ƃ̑Š�æ“I‚È‘��B—}�§Œø‰Ê�D‘æ64‰ñ“ú–{–òŠw‰ï‹ß‹EŽx•”‘�‰ï�E‘å‰ï (‹ž“s), 2014.10.

 

14)   �¬�ì‰À�D�A’Ò–{‰ë”V�A‹g“c‘ñ–í�A�_Œ´Œ’Œá�A’¹‹�“Þ‰›�A•õŠ_“N–ç�A�¼Œû�HŽi�F�t”A�׊ǃ‚ƒfƒ‹HK-2�×–E‚É‚¨‚¯‚éƒCƒ“ƒhƒLƒVƒ‹—°Ž_‚Ì“®‘Ô‚É‹y‚Ú‚·”AŽ_‚̉e‹¿�D‘æ8‰ñ“ú–{�t‘Ÿ•a–ò•¨—Ö@Šw‰ïŠw�p�W‰ï�E‘�‰ï2014 (‘å�ã), 2014.10. —D�G‰‰‘è�ÜŽó�Ü

 

15)   ˆÉ“¡‚Ȃ‚±�A’Ò–{‰ë”V�A“àŽR�m�A�¬àV�«ˆê�A�X‰º’qŒb�AŒÃ‹v•Û‘ñ�A˜a�ò’q�AŽR�ì’q”V�A—§–Ø�G�®�A•õŠ_“N–ç�A�¼Œû�HŽi�Fƒqƒg‘å’°Šà—R—ˆ�×–EŠ”LS180�×–E‚Ì�RŠà�ÜŠ´Žó�«‚É‹y‚Ú‚·––Šú�t•s‘SгŽÒŒŒ�´‚̉e‹¿�D‘æ35‰ñ“ú–{—Õ�°–ò—�Šw‰ïŠw�p‘�‰ï (�¼ŽR), 2014.12.

 

�u‰‰“™

 

1)   ’Ò–{‰ë”V�F“Á•Ê�u‰‰�u–ò–òŠw˜AŒg‚É‚æ‚éƒGƒrƒfƒ“ƒX‘n�»‚ð–ÚŽw‚µ‚Ä�`ƒGƒrƒfƒ“ƒX‚È‚«�펯‚Ö‚Ì’§�í�`�v.�@‘æ11‰ñPharm. Café (‘å�ã), 2014.3.

 

2)   �¼Œû�HŽi�FƒVƒ“ƒ|ƒWƒEƒ€�uƒWƒFƒlƒŠƒbƒNˆã–ò•i‚Ì�»�Ü•iŽ¿•]‰¿�v.�@“ú–{•a‰@–ò�ÜŽt‰ï“Œ–kƒuƒ�ƒbƒN‘æ4‰ñŠw�p‘å‰ï (�å‘ä), 2014.5.

 

3)   �¼Œû�HŽi�F‹ž“s–ò‰È‘åŠw‘åŠw�à–¾‰ï (–¼ŒÃ‰®), 2014.8.

 

4)�@’Ò–{‰ë”V�FƒI�[ƒKƒiƒCƒU�[ Œ“ ‰‰ŽÒ�@ƒ��[ƒNƒVƒ‡ƒbƒv�@–òŠw�¶‚Ì‚½‚߂̊î‘b‚©‚çŠw‚ÔCKD–ò•¨—Ö@�uŽåŽ|�à–¾�`–òŠw•”‚ÅŠw‚ñ‚¾‚±‚Æ‚ªŽÀ—Õ�°‚łǂ¤Šˆ‚©‚¹‚é‚Ì‚©�H�`�v. ‘æ8‰ñ“ú–{�t‘Ÿ•a–ò•¨—Ö@Šw‰ïŠw�p�W‰ï�E‘�‰ï2014 (‘å�ã), 2014.10.

 

‚»‚Ì‘¼

 

1)�@�¼Œû�HŽi�FŽQ‰Á�@•½�¬26”N“x–òŠw‹¤—pŽŽŒ±OSCE�à–¾‰ï (‹ž“s), 2014.4.

 

2)�@�¼Œû�HŽi�A’Ò–{‰ë”V�A•õŠ_“N–ç: ‘ÌŒ±ŽÀ�K�u�ì‚낤“î�p�IŽg‚¨‚¤“î�p�I�v. ‹ž“s–ò‰È‘åŠwƒI�[ƒvƒ“ƒLƒƒƒ“ƒpƒX (‹ž“s), 2014.8.

 

3)  ‰ª�è�^”g�A’Ò–{‰ë”V�A�¬�o”Ž‹`�AŽO‰Y—L‰Ô—¢�A•õŠ_“N–ç�A�¼Œû�HŽi�FSN-38‚Ì�×–E‘��B—}�§Œø‰Ê‚É‹y‚Ú‚·ƒR�[ƒq�[�ˆ’u‚̉e‹¿�D‘æ4‰ñ4‘åŠw˜AŒgŒ¤‹†ƒtƒH�[ƒ‰ƒ€ (‹ž“s), 2014.12.